BeOne Medicines AG (ONC) Revenue by Segment
BeOne Medicines revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), BeOne Medicines's largest product or service was Brukinsa, with $1.25 billion or 73% of revenue, up 31.4% from a year earlier. Next: Tevimbra (13%), Xgeva (6%) and Other (2%).
By region, United States brought in 54%, China brought in 30% and Europe brought in 12% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Brukinsa (+31.4%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
BeOne Medicines AG
Revenue breakdown
Fiscal quarters, from company filings
BeOne Medicines revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Brukinsa | $1.2B | – | – | $949.8M | 73% |
| Tevimbra | $228.5M | – | – | $193.5M | 13% |
| Xgeva | $104.5M | – | – | $81.3M | 6% |
| Other | $37.8M | – | – | $21.1M | 2% |
| Blincyto | $36.5M | – | – | $25.6M | 2% |
| Other Revenue | $25.3M | $26.1M | $17.3M | $13.2M | 1% |
| Kyprolis | $15.1M | – | – | $19.4M | 1% |
| Pobevcy | $9.6M | – | – | $11.2M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
BeOne Medicines revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $914.2M | $782.3M | $754.9M | $694.4M | 54% |
| China | $506.0M | $472.0M | $439.9M | $432.9M | 30% |
| Europe | $208.8M | $194.0M | $166.6M | $152.4M | 12% |
| All Other Countries Except China and United States of America | $76.1M | $65.2M | $51.0M | $35.6M | 4% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for BeOne Medicines?
Brukinsa: $1.25 billion, or 73% of revenue, in Q2 fiscal 2026.
What are BeOne Medicines's main products and services?
By revenue in Q2 fiscal 2026: Brukinsa (73%), Tevimbra (13%), Xgeva (6%) and Other (2%).
Where does BeOne Medicines make its money?
By region in Q2 fiscal 2026: United States (54%), China (30%), Europe (12%) and All Other Countries Except China and United States of America (4%).
